Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 and ...

"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

But the Dow Jones Industrial Average (^DJI 0.65% ... making it the second most valuable U.S.-based healthcare company behind Eli Lilly. The stock got pummeled in December due to controversy ...

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast ...

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly said it received Food and Drug Administration approval ...

Eli Lilly (LLY) stock sinks after cutting its fourth quarter revenue guidance, expecting its GLP-1 weight-loss drug sales to fall below expectations. To watch more expert insights and analysis on ...

Warren Buffett Owns 6 Dow Jones Stocks. Here's the Best of the Bunch for Income Investors to Buy Right Now.

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average ... Image source: Getty Images. Eli Lilly (NYSE: LLY) is the maker of one of today's most ...

Eli Lilly has agreed to acquire Scorpion Therapeutics' breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...